SG Americas Securities LLC Reduces Holdings in Xenon Pharmaceuticals Inc. $XENE

SG Americas Securities LLC reduced its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 63.9% in the third quarter, Holdings Channel reports. The institutional investor owned 6,928 shares of the biopharmaceutical company’s stock after selling 12,249 shares during the period. SG Americas Securities LLC’s holdings in Xenon Pharmaceuticals were worth $278,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the business. Holocene Advisors LP bought a new stake in shares of Xenon Pharmaceuticals during the 2nd quarter valued at $56,637,000. Geode Capital Management LLC grew its holdings in Xenon Pharmaceuticals by 1,294.2% during the second quarter. Geode Capital Management LLC now owns 970,343 shares of the biopharmaceutical company’s stock valued at $30,369,000 after purchasing an additional 900,746 shares during the period. Braidwell LP increased its position in Xenon Pharmaceuticals by 33.0% in the second quarter. Braidwell LP now owns 3,605,029 shares of the biopharmaceutical company’s stock worth $112,837,000 after buying an additional 895,154 shares in the last quarter. Vestal Point Capital LP raised its stake in shares of Xenon Pharmaceuticals by 53.8% in the second quarter. Vestal Point Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock worth $62,600,000 after buying an additional 700,000 shares during the period. Finally, Commodore Capital LP lifted its position in shares of Xenon Pharmaceuticals by 30.1% during the 2nd quarter. Commodore Capital LP now owns 3,025,000 shares of the biopharmaceutical company’s stock valued at $94,682,000 after buying an additional 700,000 shares in the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Insider Activity

In other news, CEO Ian Mortimer sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $44.43, for a total transaction of $1,777,200.00. Following the sale, the chief executive officer directly owned 6,000 shares of the company’s stock, valued at $266,580. This represents a 86.96% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders sold 65,302 shares of company stock worth $2,924,128. 4.07% of the stock is owned by corporate insiders.

Xenon Pharmaceuticals Stock Up 0.5%

Shares of XENE stock opened at $42.39 on Wednesday. The company’s fifty day simple moving average is $42.99 and its two-hundred day simple moving average is $39.46. Xenon Pharmaceuticals Inc. has a 52 week low of $26.74 and a 52 week high of $46.60. The stock has a market cap of $3.28 billion, a P/E ratio of -10.90 and a beta of 0.97.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Monday, November 3rd. The biopharmaceutical company reported ($1.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.01. The firm’s revenue was up .0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.81) earnings per share. On average, analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on XENE. Royal Bank Of Canada increased their target price on shares of Xenon Pharmaceuticals from $55.00 to $58.00 and gave the stock an “outperform” rating in a report on Tuesday, November 4th. Cantor Fitzgerald reissued an “overweight” rating and issued a $55.00 price objective on shares of Xenon Pharmaceuticals in a research note on Tuesday, November 4th. Needham & Company LLC restated a “buy” rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a research note on Tuesday, November 4th. Bloom Burton raised shares of Xenon Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, October 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a report on Friday, January 9th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $54.82.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.